Off-label prescribing common, study shows
If you prescribe medications off-label, you’re not alone. A Canadian study of primary care physicians show the practice is quite common, according to results published in the Archives of Internal Medicine.
Researchers from McGill University in Montreal studied 113 primary care physicians who wrote 253,347 electronic prescriptions for 50,823 patients from January 2005 through December 2009.
Overall, 11% of medications were prescribed for an off-label indication, and 79% of off-label use lacked strong scientific evidence, the results indicate. The authors noted the magnitude of off-label use was less than in a 2006 U.S. study, which showed a rate of 21%.
Off-label prescribing varied by medication, patient, and physician characteristics, according to authors. The highest proportion of off-label prescribing involved central nervous system medications (26.3%), anti-infective agents (17.1%), and ear-nose-throat medications (15.2%), according to the results.
The results indicate that medications with three or four approved indications were associated with lower off-label use compared with those with one or two approved indications. Medications approved after 1995 also were associated with lower off-label use than those approved before 1981. Physicians with high scores on evidence-based methods were less likely to prescribe off-label.
“Our findings indicate that off-label prescribing is common in primary care and varies by drug class, the number of approved indications for the drug, the age of the drug, patients’ sex and physicians’ attitude toward evidence-based medicine,” the authors write. “Electronic health records can be used to document treatment indication at the time of prescribing and may pave the way for enhanced postmarketing evaluation of drugs if linked to treatment outcomes.”
In an accompanying editorial, Patrick G. O’Malley, MD, MPH, of the Uniformed Services University of the Health Sciences, Bethesda, Maryland, writes that physicians prescribe off-label occasionally when their patients’ conditions aren’t responding to available treatments.
“Here is my view about a way forward on this topic,” he writes. “First, the discourse needs to focus less on overuse or underuse or off-label use and more on evolving toward better measurement of use, better assessment of appropriate use based on linkage to clinical outcomes, and better processes to optimize use.”
MORE ARTICLES IN THIS ISSUE
The price of common health screenings varies as much as 755%, even within the same geographic areas, a study shows. Find out which tests had the biggest gaps--and where your practice falls in the ranges.
Electronic health information exchange is a concern for you--and for lawmakers. A briefing for top U.S. Senate staff members discussed possible solutions.
A public-private care coordination program could pay for participating physicians. Find out whether you qualify.
Survey shows doctors under the age of 40 would prefer to own their practices or join small groups. Learn why they find their employment options frustrating.
Our exclusive interview with a physician leader involved in the CMS Shared Savings Program reveals what she hopes to achieve through the program. Could your practice learn from her experience?